RET and non-small cell lung carcinoma: Therefore, standard monitoring after initiation of targeted agents typically includes baseline and periodic assessment of renal function, electrolytes, and tumor markers, though specific protocols vary by agent and clinical context. We report an unusual case of TLS following selpercatinib initiation in rearranged during transfection (RET) fusion-positive non-small-cell lung cancer.